These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 8489450

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP, Söderström M, Rouland JF, Malecaze F.
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [Abstract] [Full Text] [Related]

  • 9. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K, Zimmerman TJ, Downes N, Schoenfelder J, Xalacom/Latanoprost Study Group.
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [Abstract] [Full Text] [Related]

  • 10. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability.
    Widengård I, Mäepea O, Alm A.
    Br J Ophthalmol; 1998 Apr; 82(4):404-6. PubMed ID: 9640189
    [Abstract] [Full Text] [Related]

  • 11. Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.
    Aung T, Chew PT, Oen FT, Chan YH, Thean LH, Yip L, Lim BA, Soh J, Seah SK.
    Br J Ophthalmol; 2002 Jan; 86(1):75-9. PubMed ID: 11801508
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
    Casson RJ, Liu L, Graham SL, Morgan WH, Grigg JR, Galanopoulos A, Crawford A, House PH.
    J Glaucoma; 2009 Jan; 18(8):582-8. PubMed ID: 19826386
    [Abstract] [Full Text] [Related]

  • 13. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
    Hotehama Y, Mishima HK, Kitazawa Y, Masuda K.
    Jpn J Ophthalmol; 1993 Jan; 37(3):270-4. PubMed ID: 8295364
    [Abstract] [Full Text] [Related]

  • 14. Potential mechanism for the additivity of pilocarpine and latanoprost.
    Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME.
    Am J Ophthalmol; 2001 Jun; 131(6):722-8. PubMed ID: 11384567
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [Abstract] [Full Text] [Related]

  • 16. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group.
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [Abstract] [Full Text] [Related]

  • 17. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M, K-115 Clinical Study Group.
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [Abstract] [Full Text] [Related]

  • 18. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Parrish RK, Palmberg P, Sheu WP, XLT Study Group.
    Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
    [Abstract] [Full Text] [Related]

  • 19. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R, Hwang LJ, Grunden JW, Bean GW.
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [Abstract] [Full Text] [Related]

  • 20. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M, Reis A, Sano ME, Susanna R.
    J Glaucoma; 2010 Jan; 19(5):331-5. PubMed ID: 19730119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.